Does the addition of recLH (Luveris [lutropin alfa]) to a regimen of recFSH (Gonal-F [follitropin alfa]) and GnRH antagonist (Cetrotide [cetrorelix]) improve ovarian response and implantation rates in patients age greater than 35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2010
At a glance
- Drugs Lutropin alfa (Primary) ; Cetrorelix; Follitropin alfa
- Indications Female infertility
- Focus Therapeutic Use
- Acronyms Luveris study
- 01 Jan 2010 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials.
- 25 Nov 2006 New trial record.